氨溴索聯(lián)合亞胺培南治療重癥肺炎的臨床效果

打開文本圖片集

【摘要】目的：分析氨溴索聯(lián)合亞胺培南治療重癥肺炎的臨床效果。方法：選取我院2019年6月—2022年6月的82例重癥肺炎患者，隨機將其分成為兩組。對照組采取亞胺培南，觀察組聯(lián)合采取氨溴索。結果：治療前，兩組的血清SAA、PCT、WBC計數(shù)、IL-1β和CRP水平無明顯差異（P>0.05），治療后，兩組的血清SAA、PCT、WBC計數(shù)、IL-1β和CRP水平均明顯降低（P0.05），治療后，兩組的PaO2、PaO2 /FiO2水平均明顯升高（P

【關鍵詞】氨溴索；亞胺培南；重癥肺炎

Clinical effect of ambroxol combined with imipenem in the treatment of severe pneumonia

DUAN Baoxia

First People’s Hospital of Tianshui， Tianshui， Gansu 741000， China

【Abstract】Objective： To analyze the clinical effect of ambroxol combined with imipenem in the treatment of severe pneumonia. Methods： A total of 82 patients with severe pneumonia in our hospital from June 2019 to June 2022 were selected and randomly divided into two groups. The control group took imipenem， and the observation group took ambroxol. Results： Before treatment， there was no significant difference in serum SAA， PCT， WBC count， IL-1β and CRP levels between the two groups （P>0.05）. After treatment， serum SAA， PCT， WBC count， IL-1β and CRP levels in both groups were significantly decreased （P0.05）. After treatment， the levels of PaO2 and PaO2 /FiO2 in the two groups were significantly increased （P

【Key Words】Ambroxol； Imipenem； Severe pneumonia

重癥肺炎指的是患者的病灶部位累及機體內多個肺葉，導致肺實質發(fā)生嚴重感染的一種臨床急重癥，病原菌主要為細菌、支原體、真菌和病毒等。（剩余4326字）